Marinus Pharmaceuticals (NASDAQ:MRNS) Upgraded to Outperform by Oppenheimer
Marinus Pharmaceuticals (NASDAQ:MRNS – Get Free Report) was upgraded by research analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a note issued to investors on Monday, MarketBeat.com reports. The firm currently has a $6.00 price objective on the biopharmaceutical company’s stock. Oppenheimer’s price objective would suggest a potential upside of […]
More Stories
Craig Scott Billings Sells 18,000 Shares of AppLovin Co. (NASDAQ:APP) Stock
AppLovin Co. (NASDAQ:APP – Get Free Report) Director Craig Scott Billings sold 18,000 shares of the business’s stock in a...
DiaSorin (OTCMKTS:DSRLF) Hits New 52-Week High – What’s Next?
DiaSorin S.p.A. (OTCMKTS:DSRLF – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Friday ....
Ibstock (LON:IBST) Stock Price Passes Below 50 Day Moving Average – Should You Sell?
Ibstock plc (LON:IBST – Get Free Report) passed below its 50-day moving average during trading on Wednesday . The stock...
Templeton Emerging Markets Investment Trust (LON:TEM) Share Price Passes Below Fifty Day Moving Average – Time to Sell?
Templeton Emerging Markets Investment Trust plc (LON:TEM – Get Free Report)’s share price crossed below its 50-day moving average during...
Transat A.T. (TSE:TRZ) Stock Crosses Below 50 Day Moving Average – Here’s Why
Transat A.T. Inc. (TSE:TRZ – Get Free Report) crossed below its 50 day moving average during trading on Wednesday ....
Tilly’s (NYSE:TLYS) Stock Crosses Below 50-Day Moving Average – Time to Sell?
Tilly’s, Inc. (NYSE:TLYS – Get Free Report) shares passed below its fifty day moving average during trading on Wednesday ....